Evidence map›Paper›PMID 26193819›Full record

ArticleBiometrics2015

Using decision lists to construct interpretable and parsimonious treatment regimes.

Yichi Zhang, Eric B Laber, Anastasios Tsiatis, Marie Davidian

Abstract read
In one paragraph

Article in Biometrics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Machine Learning and Health Science Research: Tutorial.Journal of medical Internet research · 2024
    Article
  8. Transfer learning of individualized treatment rules from experimental to real-world data.Journal of computational and graphical statistics : a joint publication of American Statistical Association, Institute of Mathematical Statistics, Interface Foundation of North America · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Focusing on optimality for the translation of precision medicine.Journal of clinical and translational science · 2022
    Article
  13. Meta-analysis of individualized treatment rules via sign-coherency.Proceedings of machine learning research · 2022
    Article
  14. Article
  15. High-Dimensional Precision Medicine From Patient-Derived Xenografts.Journal of the American Statistical Association · 2021
    Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yichi ZhangDepartment of Statistics, North Carolina State University, Raleigh, NC 27695-8203, U.S.A.
Eric B LaberDepartment of Statistics, North Carolina State University, Raleigh, NC 27695-8203, U.S.A.
Anastasios TsiatisDepartment of Statistics, North Carolina State University, Raleigh, NC 27695-8203, U.S.A.
Marie DavidianDepartment of Statistics, North Carolina State University, Raleigh, NC 27695-8203, U.S.A.

Funding

Statistical Methods for Cancer Clinical TrialsP01CA142538 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVIDIAN, MARIE, KOSOROK, MICHAEL R · 2010 to 2019
$21.3M
Flexible Statistical Methods for Biomedical DataR01CA085848 · NCI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI DAVIDIAN, MARIE · 2000 to 2015
$3.1M
Statistical Methods for Complex Data in Cardiovascular DiseaseR01HL118336 · NHLBI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI O'BRIEN, SEAN M, TSIATIS, ANASTASIOS A · 2013 to 2016
$1.5M
NCI NIH HHS P01 CA142538NCI NIH HHS R01 CA085848NHLBI NIH HHS R01 HL118336
6 · The paper itself

Abstract

A treatment regime formalizes personalized medicine as a function from individual patient characteristics to a recommended treatment. A high-quality treatment regime can improve patient outcomes while reducing cost, resource consumption, and treatment burden. Thus, there is tremendous interest in estimating treatment regimes from observational and randomized studies. However, the development of treatment regimes for application in clinical practice requires the long-term, joint effort of statisticians and clinical scientists. In this collaborative process, the statistician must integrate clinical science into the statistical models underlying a treatment regime and the clinician must scrutinize the estimated treatment regime for scientific validity. To facilitate meaningful information exchange, it is important that estimated treatment regimes be interpretable in a subject-matter context. We propose a simple, yet flexible class of treatment regimes whose members are representable as a short list of if-then statements. Regimes in this class are immediately interpretable and are therefore an appealing choice for broad application in practice. We derive a robust estimator of the optimal regime within this class and demonstrate its finite sample performance using simulation experiments. The proposed method is illustrated with data from two clinical trials.

Indexed as

Clinical ProtocolsDecision TreesBiometryBreast NeoplasmsClinical Trials as TopicComputer SimulationDepressionEvidence-Based MedicineFemaleHumansModels, StatisticalPrecision MedicineDecision listsExploratory analysesInterpretabilityPersonalized medicineTreatment regimes

Identifiers

PMID26193819
PMCPMC4715597

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.